Latest Period
Q4 2025
Security Snapshot
Theriva Biologics, Inc. - Common stock (TOVX) Institutional Ownership
CUSIP: 87164U508
13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026
Institutions Reporting
20
Shares (Excl. Options)
1,295,504
Price
$0.21
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common stock
- Symbol
- TOVX on NYSE
- Shares outstanding
- 9,600,143
- Price per share
- $0.25
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 1,295,504
- Total reported value
- $272,379
- % of total 13F portfolios
- 0%
- Share change
- +858,452
- Value change
- +$158,821
- Number of holders
- 20
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- TOVX - Theriva Biologics, Inc. - Common stock is tracked under CUSIP 87164U508.
- 20 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 20 to 2 between Q4 2025 and Q1 2026.
- Reported value moved from $272,379 to $28.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 20 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 87164U508?
CUSIP 87164U508 identifies TOVX - Theriva Biologics, Inc. - Common stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 87164U508:
Significant Owners of Theriva Biologics, Inc. - Common stock (TOVX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Jeffrey Matthew Gryga Irrevocable Trust | 7.7% | $300,046 | 739,211 | Jeffrey Matthew Gryga Irrevocable Trust | 24 Oct 2025 | |||
| Empery Asset Management, LP | 5% | -50% | $201,636 | -$179,638 | 504,091 | -47% | Empery Asset Management, LP | 30 Sep 2025 |
| CVI Investments, Inc. | 4.9% | $206,052 | 146,136 | CVI Investments, Inc. | 31 Dec 2024 |
As of 31 Dec 2025, 20 institutional investors reported holding 1,295,504 shares of Theriva Biologics, Inc. - Common stock (TOVX). This represents 13% of the company’s total 9,600,143 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Theriva Biologics, Inc. - Common stock (TOVX) together control 13% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD GROUP INC | 2.7% | 255,727 | +1461% | 0% | $53,703 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 212,087 | +652% | 0% | $44,622 |
| MORGAN STANLEY | 2.1% | 200,000 | 0% | $42,080 | |
| UBS Group AG | 2% | 191,410 | +735% | 0% | $40,196 |
| Ikarian Capital, LLC | 1.2% | 112,076 | -6.6% | 0% | $23,580 |
| TWO SIGMA SECURITIES, LLC | 0.45% | 42,893 | 0% | $9,025 | |
| TWO SIGMA INVESTMENTS, LP | 0.44% | 42,337 | -32% | 0% | $8,908 |
| DRW Securities, LLC | 0.43% | 41,745 | 0% | $8,783 | |
| XTX Topco Ltd | 0.41% | 39,445 | +20% | 0% | $8,299 |
| StoneX Group Inc. | 0.39% | 37,217 | 0% | $7,830 | |
| BARCLAYS PLC | 0.34% | 32,569 | 0% | $6,853 | |
| BANK OF AMERICA CORP /DE/ | 0.32% | 31,139 | +38824% | 0% | $6,539 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.29% | 27,646 | -22% | 0% | $5,817 |
| SCHWARZ DYGOS WHEELER INVESTMENT ADVISORS LLC | 0.16% | 15,000 | 0% | $3,156 | |
| BlackRock, Inc. | 0.08% | 7,504 | -0.03% | 0% | $1,579 |
| CITIGROUP INC | 0.06% | 6,189 | 0% | $1,302 | |
| OSAIC HOLDINGS, INC. | 0% | 445 | +0.23% | 0% | $92 |
| SBI Securities Co., Ltd. | 0% | 59 | 0% | 0% | $12 |
| IFP Advisors, Inc | 0% | 11 | 0% | 0% | $2 |
| Newbridge Financial Services Group, Inc. | 0% | 5 | 0% | $1 | |
| Virtu Financial LLC | 0% | 0 | -100% | $0 | |
| TWO SIGMA ADVISERS, LP | 0% | 0 | -100% | $0 | |
| HRT FINANCIAL LP | 0% | 0 | -100% | $0 | |
| JANE STREET GROUP, LLC | 0% | 0 | -100% | $0 | |
| Wealthspire Advisors, LLC | 0% | 0 | -100% | $0 |
Institutional Holders of Theriva Biologics, Inc. - Common stock (TOVX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 142 | $28 | +$14 | $0.19 | 2 |
| 2025 Q4 | 1,295,504 | $272,379 | +$158,821 | $0.21 | 20 |
| 2025 Q3 | 437,052 | $177,030 | +$57,424 | $0.41 | 18 |
| 2025 Q2 | 291,012 | $126,275 | +$38,331 | $0.43 | 15 |
| 2025 Q1 | 190,681 | $209,751 | +$165,878 | $1.10 | 10 |
| 2024 Q4 | 34,470 | $60,323 | -$627,703 | $1.75 | 9 |
| 2024 Q3 | 491,424 | $677,871 | +$471,525 | $1.38 | 16 |